Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-finding Study of SI-613 in Patients with Enthesopathy(Japan. Phase II)

Next Previous
X
Search
Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-finding Study of SI-613 in Patients with Enthesopathy(Japan. Phase II)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Diclofenac-Eatlhyaluronate (Primary)
  • Indications Plantar fasciitis; Tennis elbow
  • Focus Therapeutic Use
  • Sponsors Seikagaku Corporation

    • Most Recent Events

    • 12 May 2023 According to a Seikagaku Corporation media release, in February 2022, development of SI-613-ETP was discontinued since primary efficacy endpoint was not met, and the Company will prioritize identification of the cause of shock or anaphylaxis of JOYCLE.
    • 12 May 2023 Status changed from active, no longer recruiting to discontinued, according to a Seikagaku Corporation media release.
    • 10 Oct 2018 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top